VANCOUVER, British Columbia and WARMINSTER, Pa., June 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation
(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David
Hastings as Chief Financial Officer, effective June 11, 2018. Mr. Hastings will assume the CFO role from Koert VandenEnden,
Arbutus' interim Chief Financial Officer.
"We’re excited to welcome David Hastings to Arbutus as our new CFO," said Dr. Mark J Murray, CEO of Arbutus.
"David brings extensive financial, operational, and strategic experience in the biotech industry, and will be a great asset to us
as we further advance toward our goal of delivering a cure for chronic HBV and seek to maximize value for shareholders.”
Mr. Hastings previously served as the Chief Financial Officer and Executive Vice President of Incyte Corporation
(a life sciences company focused on oncology) from 2003 until 2014. During this time, Mr. Hastings oversaw all financial aspects as
Incyte transitioned from research and development to commercialization following the launch of Jakafi®(ruxolitinib). Mr. Hastings
also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. During his tenure at ArQule, he
played an important role in ArQule's transition into a drug discovery and development organization, and in two strategic
acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Prior to that, Mr. Hastings was with Genzyme Corporation as its
Vice President and Corporate Controller, and with Sepracor, Inc. where he was Director of Finance. Most recently, Mr. Hastings
served as the Chief Financial Officer and Senior Vice President of Unilife Corporation (a medical device company) from 2015 to 2017
and as its Chief Accounting Officer and Treasurer from 2016 to 2017.
"I look forward to joining the Arbutus team and am excited about Arbutus’s mission to cure chronic HBV, a
significant unmet medical need,” said David Hastings. “I believe Arbutus is well positioned scientifically, operationally and
financially to achieve this all important goal.”
Mr. VandenEnden, Arbutus' current interim Chief Financial Officer, will remain as a member of the executive
leadership team in the role of Chief Accounting Officer and will continue to act as Arbutus' Principal Accounting Officer during a
period of transition to Mr. Hastings.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to
discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is
developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to
a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit
www.arbutusbio.com.
Contact Information
Investors
Mark Murray
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: david.schull@russopartnersllc.com
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws
(collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about Mr.
Hastings acting as CFO of the Arbutus; Mr. VandenEnden’s role within the executive leadership team; and discovering, developing and
commercializing a cure for patients suffering from chronic HBV infection.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous
assumptions regarding, among other things: the continued availability of Mr. Hastings and Mr. VandenEnden; the effectiveness and
timeliness of preclinical and clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; the timing
of regulatory approvals; and the stability of economic and market conditions. While Arbutus considers these assumptions to be
reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social
uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements contained herein. Known risk factors include, among others: Mr. Hastings or Mr. VandenEnden may become
unavailable to serve their executive leadership positions for Arbutus; anticipated pre-clinical and clinical trials may never be
initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not
receive the necessary regulatory approvals for the clinical development of their products on a timely basis, if at all; economic
and market conditions may worsen; and market shifts may require a change in strategic focus.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on
Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or
update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or developments, except as required by law.
